Log In
Print
BCIQ
Print
Print this Print this
 

Remyelinating antibody (rHIgM22)

  Manage Alerts
Collapse Summary General Information
Company Acorda Therapeutics Inc.
DescriptionRecombinant human mAb for promotion of remyelination
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today